1. Home
  2. APLM vs GIPR Comparison

APLM vs GIPR Comparison

Compare APLM & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GIPR
  • Stock Information
  • Founded
  • APLM 2016
  • GIPR 2015
  • Country
  • APLM United States
  • GIPR United States
  • Employees
  • APLM N/A
  • GIPR N/A
  • Industry
  • APLM Blank Checks
  • GIPR Real Estate Investment Trusts
  • Sector
  • APLM Finance
  • GIPR Real Estate
  • Exchange
  • APLM Nasdaq
  • GIPR Nasdaq
  • Market Cap
  • APLM 6.9M
  • GIPR 7.7M
  • IPO Year
  • APLM N/A
  • GIPR 2021
  • Fundamental
  • Price
  • APLM $6.49
  • GIPR $1.55
  • Analyst Decision
  • APLM
  • GIPR
  • Analyst Count
  • APLM 0
  • GIPR 0
  • Target Price
  • APLM N/A
  • GIPR N/A
  • AVG Volume (30 Days)
  • APLM 7.8K
  • GIPR 17.2K
  • Earning Date
  • APLM 08-13-2025
  • GIPR 08-14-2025
  • Dividend Yield
  • APLM N/A
  • GIPR N/A
  • EPS Growth
  • APLM N/A
  • GIPR N/A
  • EPS
  • APLM N/A
  • GIPR N/A
  • Revenue
  • APLM $198,000.00
  • GIPR $9,711,058.00
  • Revenue This Year
  • APLM $415.15
  • GIPR N/A
  • Revenue Next Year
  • APLM N/A
  • GIPR N/A
  • P/E Ratio
  • APLM N/A
  • GIPR N/A
  • Revenue Growth
  • APLM N/A
  • GIPR 11.25
  • 52 Week Low
  • APLM $4.47
  • GIPR $1.33
  • 52 Week High
  • APLM $35.98
  • GIPR $4.15
  • Technical
  • Relative Strength Index (RSI)
  • APLM 47.85
  • GIPR 53.76
  • Support Level
  • APLM $6.21
  • GIPR $1.46
  • Resistance Level
  • APLM $6.80
  • GIPR $1.55
  • Average True Range (ATR)
  • APLM 0.52
  • GIPR 0.06
  • MACD
  • APLM 0.00
  • GIPR 0.02
  • Stochastic Oscillator
  • APLM 51.61
  • GIPR 77.27

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

Share on Social Networks: